UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 2 nd , 2017

 

 

 

MEDICAL INNOVATION HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Colorado   000-27211   84-1469319
(State or Other Jurisdiction   (Commission   (I.R.S. Employer
of Incorporation)   File Number)   Identification No.)

 

5805 State Bridge Road, Suite G-328, Duluth, Georgia 30097
(Address of Principal Executive Offices) (Zip Code)

 

(866) 883-3793
(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

     
   

 

SECTION 8 — OTHER EVENTS

 

Item 8.01 MIHI Expands its Market Presence Enters Into Letter of Intent to Acquire Health and Lifestyle Supplements Company Designed for Better Living, Healthier and Longer Life.

 

     
   

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Medical Innovation Holdings, Inc.
   
  By /s/ Arturo Jake Sanchez
  Name: Arturo “Jake” Sanchez  
  Title: CEO

 

Date: February 2 nd , 2017

 

     
   

 

INDEX TO EXHIBITS

 

Exhibit No.   Description
99.1   Press Release

 

     
   

 

 

 

News Release

 

MIHI Expands its Market Presence Enters Into Letter of Intent to Acquire Health and Lifestyle Supplements Company Designed for Better Living, Healthier and Longer Life

 

Deal is company’s first in line of acquisitions that will help build the company’s portfolio with services, medical devices, laboratory testing, nutraceuticals, and other organizations.

 

DULUTH, GEORGIA – 02/02/17

 

Medical Innovation Holdings, Inc. (“MIHI” or the “Company”) (OTC: MIHI), today announced that on January 13, 2017 it has entered into a Letter of Intent (LOI) with a Florida-based nutraceutical company (NEWCO). Under the agreement MIHI will acquire 100% of the assets of NEWCO in a cash and stock transaction valued anywhere from $2.5-$3.5 million. NEWCO will provide a proprietary product line with specialized formulations along with Trademark product names. Also with the acquisition the company will receive a robust customer base, existing staff and management, and certain marketing material designed to promote NEWCO’s product line.

 

NEWCO is a nationally known research and development company recognized for its portfolio of best-in-class, physician-developed, natural health supplements designed to provide their customers with a better, healthier, and longer life. For over 16 years, NEWCO has used and continues to use the highest quality and concentration of powerful ingredients to create products that are naturally safe AND proven effective. As a socially-responsible company, they do not perform any animal testing in any of its research and development.

 

Arturo “Jake” Sanchez, CEO and Director, stated: “This is the first of many more acquisition agreements to come… we will use NEWCO as a platform company to acquire more supplement-based companies and add additional product lines. We are also benefiting our network of physician providers by increasing their access to readily available additional sources to treat their patients and to increase the practice’s revenues. Under this agreement, we are giving the medical providers the opportunity to provide the best care for their patients by incorporating the latest advances in alternative nutraceuticals into their practice versus harmful and many times unresponsive pharma developed medicines.”

 

***

 

 
 

 

About Medical Innovation Holdings, Inc.

 

MIHI, a Colorado-based publicly traded company, owns and operates strategically aligned health care service companies focused on the delivery of clinical virtual medicine (health) as a way of bringing quality medical care to all areas of need including rural and underdeveloped areas across the country. Through our wholly owned subsidiary, 3Point Care, we provide personalized high-tech high-touch telemedicine encounters pairing our virtual health specialty doctors with traditional primary doctors utilizing nextgen virtual health technologies in order to connect a patient with a multi-disciplinary specialty clinical healthcare practice. Through our other companies and relationships, we offer Affordable Care Organization (ACO) support, wellness and prevention, lab analysis and lab services, and remote diagnostic monitoring.

 

We serve a number of constituents and stakeholders interested in reducing the cost of care, enhancing the quality of care, promoting access to care, and maintaining the continuum of care.

 

For more information on MIHI, please visit the Company’s website at http://www.medicalinnovationholdings.com

 

To be added to the Company investor email list, please email investor@MedicalInnovationHoldings.com with MIHI in the subject line.

 

To leave a message please call +1-866-883-3793 for Investor Relations

 

FORWARD-LOOKING STATEMENTS

 

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

 

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov .

 

News Release

 

Investor Contacts:

 

investor@medicalinnovationholdings.com